VivaTech 2021


Andrew Hopkins



United Kingdom


Andrew Hopkins is the founder and CEO of the global pharma-tech company, Exscientia, with offices in Oxford, Miami and Osaka. Exscientia uses artificial intelligence (AI) to efficiently discover new drugs and innovative medicines to improve our abilities to discover new medicines. Dr Hopkins’s work and research methods are all focused on accelerating the time between the start of an idea to a viable new drug candidate for patients. At Exscientia, Dr Hopkins has overseen the discovery of the world’s first precision engineered drugs generated by AI to enter phase 1 human clinical trials. Prior to founding Exscientia, Dr Hopkins was the SULSA Research Professor of Translational Biology and the Chair of Medicinal Informatics at the University of Dundee. Before becoming an academic, he held various research leadership positions at Pfizer for 10 years. Hopkins holds a DPhil from the University of Oxford in Molecular Biophysics. He has been awarded Fellowships from several national academies in the UK. He lives in Oxford, UK, with his wife and daughter.